Comparative Pharmacology
Head-to-head clinical analysis: K TAB versus KLOR CON.
Peer-Reviewed Evidence
Head-to-head clinical analysis: K TAB versus KLOR CON.
K-TAB vs KLOR-CON
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Potassium ion replacement therapy; restores intracellular and extracellular potassium levels, maintaining membrane potential and cellular function.
Potassium chloride acts as a source of potassium ions, which are essential for maintenance of intracellular tonicity, transmission of nerve impulses, contraction of cardiac, skeletal, and smooth muscle, and maintenance of normal renal function. Potassium is the major cation of intracellular fluid and helps regulate acid-base balance.
Potassium chloride extended-release tablets, 20 mEq to 40 mEq orally per day in 2-4 divided doses with meals, titrated based on serum potassium levels.
Potassium chloride extended-release: 20-100 mEq per day orally, divided into 2-4 doses, titrated based on serum potassium and clinical response. Usual starting dose: 40 mEq per day.
None Documented
None Documented
7.5 hours in normal renal function; prolonged to 12-20 hours in severe renal impairment (CrCl <10 mL/min)
The terminal elimination half-life of potassium is approximately 1-1.5 hours in healthy individuals with normal renal function. In patients with impaired renal function, half-life may be prolonged, increasing the risk of hyperkalemia.
Renal (90% unchanged), fecal (10% as metabolites)
Renal excretion of potassium ions accounts for approximately 90% of elimination via the kidneys, with the remaining 10% eliminated fecally. No biliary excretion is clinically significant.
Category C
Category C
Potassium Supplement
Potassium Supplement